myTomorrows, a Dutch HealthTech firm that connects sufferers with attainable pre-approval therapies, right now introduced the shut of a €25 million financing with the intention to speed up the worldwide enlargement of its AI-driven platform and improve entry to rising therapies for sufferers worldwide.
Avego’s progress fairness funding will gasoline the worldwide enlargement of myTomorrows’ built-in pharma options to make rising therapies extra equitable and accessible for sufferers globally.
“This funding marks a pivotal step in our journey to offer each affected person, regardless of the place they dwell, a good shot at tomorrow’s therapies,” mentioned Michel van Harten, CEO of myTomorrows. “Avego’s in depth experience in life sciences, significantly BioPharma, can be instrumental as we scale our platform and broaden our impression throughout the worldwide well being panorama.”
This growth-equity funding in myTomorrows aligns with a number of notable 2025 European HealthTech funding rounds.
In Belgium, Sequana Medical secured €24 million to help the US launch of its “alfapump” gadget for persistent fluid-retention administration. In France, ArcaScience raised €6 million to reinforce AI-driven benefit-risk intelligence for drug growth. In the meantime, Finland’s CurifyLabs obtained €6.7 million to modernise the manufacturing of personalised medicines.
Whereas these firms function in adjoining segments of the broader HealthTech and BioPharma panorama, myTomorrows stands out for its concentrate on affected person entry to pre-approval therapies by an AI-enabled platform that connects physicians, trial websites, and biopharma companions.
Its spherical represents one of many extra substantial Dutch HealthTech financings reported in 2025, underlining continued investor confidence in expertise options that bridge early-stage drug growth and affected person entry.
Ronald Brus, Founder and Board Member of myTomorrows, added: “Once we based myTomorrows in 2012, we envisioned a greater strategy to join sufferers with promising therapies – one that enhances drug growth and expands entry to innovation. This funding marks the start of a subsequent section of accelerated progress and worldwide impression.”
Based in 2012, myTomorrows is a worldwide HealthTech firm that connects sufferers, physicians, trial websites, and BioPharma companions to allow earlier and higher entry to pre-approval therapies.
By means of a centralised, multi-stakeholder platform, myTomorrows combines AI-driven insights with human experience to ship tailor-made options that intention to beat a few of right now’s biggest boundaries to affected person entry.
Headquartered in Amsterdam, with an workplace in New York Metropolis, myTomorrows has supported greater than 16,900 sufferers and a pair of,800 physicians throughout 340+ websites in over 133 nations.
With greater than 300 million sufferers worldwide going through circumstances with out accredited remedy choices, and over 10,000 therapies presently in growth or awaiting approval – myTomorrows is addressing one in every of healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval therapies, which embody medical trials and expanded entry applications (EAPs).
The brand new funding will speed up myTomorrows’ worldwide progress and additional develop its AI-driven world platform that connects physicians and their sufferers, trial websites and BioPharma companions to streamline entry and perception.
It can additionally strengthen collaborations with business companions to shorten medical growth timelines and improve real-world information capabilities, supporting proof era and regulatory perception.
“Avego is proud to help myTomorrows in its mission to remodel how sufferers and physicians entry therapies in growth,” mentioned James Flexner, Managing Companion at Avego. “We consider myTomorrows is uniquely positioned to take away boundaries for sufferers and suppliers whereas serving as a necessary associate to BioPharma.”
For BioPharma companions, myTomorrows offers medical trial recruitment, expanded entry options, and real-world information assortment. For trial websites, the platform gives a unified referral administration system that enhances trial visibility and permits real-time standing updates.
EU-Startups has featured myTomorrows a number of instances – first in 2017, reporting on its €10 million funding round, and later in its 2021 roundup of top healthcare startups in the Netherlands.
